At Fisher & Paykel Healthcare Corporation Limited’s Annual Shareholders’ Meeting, held in Auckland and online today, shareholders were asked to vote on seven ordinary resolutions. As required by NZX Listing Rule 6.1, all voting was conducted by a poll.

The ordinary resolutions passed were:

Resolution 1: To elect Anna Curzon as a Director.
Resolution 2: To authorise the Directors to fix the fees and expenses of the auditor.
Resolution 3: To approve an increase to the maximum aggregate annual remuneration payable to non-executive directors.
Resolution 4: To approve the grant of discretionary long term variable remuneration instruments to Lewis Gradon.
Resolution 5: To approve the 2025 Performance Share Rights Plan – North America.
Resolution 6: To approve the 2025 Share Option Plan – North America.
Resolution 7: To approve the Employee Share Rights Plan – North America.

Details of the total number of votes cast in person, online or by a proxy holder are:
 

Resolution	For	Against	Abstain
1: To elect Anna Curzon as a Director.	439,332,659 99.88%	514,296 0.12%	27,182
2: To authorise the Directors to fix the fees and expenses of the auditor.	429,021,432 97.54%	10,823,333 2.46%	29,372
3: To approve an increase to the maximum aggregate annual remuneration payable to non-executive directors.	352,605,905 80.47%	85,601,037 19.53%	112,884
4: To approve the grant of discretionary long term variable remuneration instruments to Lewis Gradon.	429,735,033 97.98%	8,874,134 2.02%	706,131
5: To approve the 2025 Performance Share Rights Plan – North America.	432,722,619 98.55%	6,386,217 1.45%	765,307
6: To approve the 2025 Share Option Plan – North America.	431,054,743 98.16%	8,063,344 1.84%	756,056
7: To approve the Employee Share Rights Plan – North America.	438,797,705 99.93%	326,148 0.07%	750,290

As at the commencement of the meeting, Fisher & Paykel Healthcare Corporation Limited had 587,302,790 total number of voting shares on issue.  
 

Authority for this announcement
Name of person authorised to make this announcement	Raelene Leonard General Counsel & Company Secretary
Contact person for this announcement	Raelene Leonard
Contact phone number	+64 9 610 4803
Contact email address	[email protected]
Date of release through MAP	25 August 2026

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

 

Contacts:

Media Karen Knott GM Corporate Communications [email protected] +64 21 713 911   Investors Dan Adolph Head of Investor Relations [email protected] +64 22 511 4050